Guardant Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on May 24, 2024. The filing addresses Item 5.02 regarding the amendment and restatement of the Company's Executive Severance Plan following a market-focused review initiated in late 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The Compensation Committee approved an amendment to the Executive Severance Plan effective May 24, 2024. The material terms for Named Executive Officers (NEOs) remain largely consistent with the prior plan, with specific adjustments for Change in Control (CIC) scenarios and unique provisions for the Co-CEOs.
- Non-CIC Termination: Eligible executives receive 12 months of annual base salary (lump sum), a pro-rated annual target performance bonus, and 12 months of Company-paid COBRA premiums.
- CIC Termination: Eligible executives receive 18 months of annual base salary (24 months for Co-CEOs), the full annual target performance bonus, 18 months of COBRA premiums (24 months for Co-CEOs), and full vesting of outstanding equity awards.
- Co-CEO Specifics: Co-CEOs Helmy Eltoukhy and AmirAli Talasaz receive Annual RSU and PSU awards in lieu of salary and bonus. Severance for these roles is primarily satisfied through accelerated vesting of these equity awards rather than cash salary payments.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or general risk factors. The primary contingency noted is that all severance entitlements are subject to the executive's execution and non-revocation of a general release of claims.
Investor Verification Checklist
- Verify the specific vesting acceleration terms for the 2024 Long-term RSU and PSU awards granted to Co-CEOs, which supersede the general Amended Severance Plan.
- Confirm the distinction between "Non-CIC Termination" and "CIC Termination" windows (3 months prior to 1 year post-change in control) to understand payout triggers.
- Review the requirement for a general release of claims as a condition precedent for receiving any severance benefits.
- Check subsequent filings for the actual financial impact of these compensation arrangements on the Company's expense structure.